The gross margin improvement suggests a favorable shift toward higher-margin licensing and maintenance revenue, but the extreme volatility in net margin—from 19.4% in 2025Q3 to 0.5% in 2025Q4—indicates that non-operating items and tax effects distort underlying earning power. Operating margin, which ranged from 3.2% to 27.2% over the last ten quarters, better reflects the company's operating leverage, but investors should focus on cash flow rather than net income to gauge true profitability.

Despite a healthy balance sheet and low leverage, ROIC has consistently remained in the low single digits, suggesting that the company is not compounding returns on invested capital at a rate that would justify its current valuation. The drivers appear to be a combination of thin net margins relative to the capital base and asset turnover that hovers around 0.10-0.14, reflecting the lumpy nature of system sales and box office participation. This may indicate that the business is capital-intensive in its growth phase, but investors should monitor whether the shift toward JRSAs improves returns over time.

The CCC has been persistently high, driven by DSO that often exceeds 300 days, which appears to reflect the timing of revenue recognition from sales-type leases and studio payment schedules. While DPO has remained relatively stable, the extended receivables period suggests that IMAX is financing its customers' installations, which ties up cash and may not be fully captured in headline earnings. This working capital intensity is a key reason why cumulative operating cash flow ($233.6M) has exceeded cumulative net income ($80.8M) over the last ten quarters, but it also implies that future cash flows could be lumpy if receivables collection slows.

The company has been consistently reducing its debt burden, with total debt falling from $310.3M to $282.6M over the same period, and interest coverage has improved from a low of 1.47 in 2024Q2 to 11.81 in 2026Q2. This suggests that debt service is becoming more comfortable, and the low D/E ratio of 0.63 provides a cushion against industry downturns. However, the D/EBITDA ratio of 8.72 in 2026Q2 remains elevated, reflecting the cyclicality of EBITDA, and investors should monitor whether the company can sustain this deleveraging trend if box office revenues soften.

The quick ratio of 2.48 in 2026Q2 suggests that IMAX can cover its short-term obligations without relying on inventory, which is minimal given its asset-light model. The cash build from $81.0M to $159.9M over the last ten quarters provides a significant buffer against potential disruptions in the theatrical market, particularly in China. However, the high DSO and working capital cycle imply that liquidity could be strained if receivables collection slows, so the current ratio may overstate the company's ability to meet near-term cash needs.